# EGFR Exon 20 Insertion Mutation: Research Status and New Treatment Strategies

## TL;DR

This paper reviews the current status and new treatment strategies for EGFR exon 20 insertion mutations in non-small cell lung cancer.

## Contribution

The paper provides an updated summary of recent research and treatment advancements for EGFR ex20ins mutations.

## Key findings

- EGFR ex20ins mutations are resistant to traditional EGFR-TKIs and require new targeted therapies.
- Drugs like mobocertinib and evantolimab have been FDA-approved for treating EGFR ex20ins mutations.
- Combination therapies and newer drugs like sulcitinib show promise in overcoming resistance.

## Abstract

作为非小细胞肺癌（non-small cell lung cancer, NSCLC）中重要的致癌驱动基因，表皮生长因子受体外显子20插入突变（epidermal growth factor receptor exon 20 insertion, EGFR ex20ins）具有独特蛋白构象，并且对传统EGFR酪氨酸激酶抑制剂（EGFR-tyrosine kinase inhibitors, EGFR-TKIs）原发耐药。近年来，靶向EGFR ex20ins的药物探索从未停止。莫博赛替尼与埃万妥单抗率先被美国食品药品监督管理局（Food and Drug Administration, FDA）获批用于EGFR ex20ins突变NSCLC患者，随后舒沃替尼等药物取得突破，联合治疗方案的探索也有所收获。多管齐下有望克服EGFR ex20ins耐药。因此，深入了解EGFR ex20ins的分子机制并评估新型药物的有效性与差异性至关重要。本文将对相关最新研究成果进行全面总结，以期为EGFR ex20ins突变患者精准治疗提供有价值的参考。

Clinical trials about targeted drugs for EGFR exon 20 insertion mutation